Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

Recently, rasagiline has been shown to inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an enzyme that catalyzes the sixth step of glycolysis and participates in the initiation of apoptosis.

Rasagiline is a recently approved monoamine oxidase B inhibitor used in PD that is often prescribed in the early stages of treatment. Based on evidence found in laboratory models, a recent trial ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, ...

Marksans Pharma added 2.70% to Rs 296.80 after the company reported 15.8% increase in consolidated net profit to Rs 96.72 crore on 20.83% rise in revenue from operations to Rs 641.92 crore in Q2 FY25 ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

For a long time, the holy grail of Parkinson's development [has been] to really focus on a cure or some kind of disease-modifying therapy,” explained Case. “However, there are a lot of challenges in ...